RayzeBio

NCT05595460

Phase 1, Active, not recruiting, 2022, 21 people, 27 Oct 2022, clinicaltrials.gov

Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

Phase 3, Active, not recruiting, 2022, 343 people, 28 Jul 2022, clinicaltrials.gov

Pre-diagnosis plasma cell-free DNA reveals early signatures of prostate and breast cancer risk up to eight years prior to clinical detection

Grants or research support, 21 Sept 2026, pubmed.ncbi.nlm.nih.gov